Observational Study Evaluating Long-Term Safety and Effectiveness

of Humira in Patients With Hidradenitis Suppurativa


ID# NCT03894956

Recruitment Status:  recruiting as of August 2020.


Estimated Completion Date: April 30, 2023


Sponsors and Collaborators: AbbVie

Information provided by (Responsible Party): AbbVie

Brief Summary: The objective of this study is to evaluate the long-term safety and effectiveness of Humira in patients with Hidradenitis Suppurativa (HS) in real-world clinical practice in Japan.

Please link complete details https://clinicaltrials.gov/ct2/show/NCT03894956

Locations: Japan

Contact: AbbVie GK Clinical Trial Registration Desk, +81-3-4577-1111, abbvie_jpn_info_clingov@abbvie.com


© 2021 by HS Connect, LLC  |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579